Paul H Gordon
Affiliation: Indian Health Service
- Prevalence of Parkinson disease among the Navajo: a preliminary examinationPaul H Gordon
Division of Neurology, Northern Navajo Medical Center, Shiprock, NM 87420, USA
J Parkinsons Dis 3:193-8. 2013..The prevalence of Parkinson disease (PD) varies by geographic location and ethnicity, but has never been studied among the Navajo...
- Incidence of amyotrophic lateral sclerosis among American Indians and Alaska nativesPaul H Gordon
Northern Navajo Medical Center, Medical Staff Office, Hwy 491 N, Shiprock, NM 87420, USA
JAMA Neurol 70:476-80. 2013..In the ongoing search for susceptibility genes, studying particular racial groups, such as AI/ANs,might facilitate the identification of new mutations...
- Parkinson's disease among American Indians and Alaska natives: a nationwide prevalence studyPaul H Gordon
Indian Health Service, U S Department of Health and Human Services, Northern Navajo Medical Center, Shiprock, New Mexico 87420, USA
Mov Disord 27:1456-9. 2012..The objective of this study was to determine the prevalence of Parkinson's disease (PD) among American Indian and Alaska Native (AI/AN) people...
- A prospective cohort study of neuropsychological test performance in ALSPaul H Gordon
Department of Neurology, Columbia University, New York, NY, USA
Amyotroph Lateral Scler 11:312-20. 2010..The strongest neuropsychological predictors of cognitive status were measures of executive, episodic memory and language function. Cognitively impaired patients had shorter survival time...
- Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trialPaul H Gordon
Department of Neurology, Columbia University, New York, NY, USA
Lancet Neurol 6:1045-53. 2007..Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS)...
- An observational study of cognitive impairment in amyotrophic lateral sclerosisGregory A Rippon
Department of Neurology, Gertrude H Sergievsky Center, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Eleanor and Lou Gehrig MDA ALS Research Center, New York, NY, USA
Arch Neurol 63:345-52. 2006..Clinical and pathologic features overlap in frontotemporal lobar dementia and ALS. Demographics, respiratory status, bulbar site of onset, and disease severity are potential risk factors for cognitive impairment in ALS...
- Outcome measures for early phase clinical trialsPaul H Gordon
Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
Amyotroph Lateral Scler 8:270-3. 2007..The ALSFRS-R most strongly predicted survival and provided the most complete data, but large changes may be necessary before patients perceive treatment effects...
- A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALSPaul H Gordon
Department of Neurology, Columbia University, New York, USA
Amyotroph Lateral Scler 9:212-22. 2008..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...
- A screening assessment of cognitive impairment in patients with ALSPaul H Gordon
Departmen of Neurology, Columbia University, New York, USA
Amyotroph Lateral Scler 8:362-5. 2007..Behavioral and motor impairment is associated with depressive symptoms in caregivers. Studies with formal neuropsychological tests are needed to determine the sensitivity and specificity of the screen in ALS...
- Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trialPetra Kaufmann
Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, New York, NY, USA
Amyotroph Lateral Scler 8:42-6. 2007..97 (95% CI 0.93-0.98). We conclude that the ALSFRS-R shows excellent inter- and intra-rater reliability, and reliability of telephone administration when used as primary outcome measure in a multicenter ALS trial...
- Modafinil treatment of fatigue in patients with ALS: a placebo-controlled studyJudith G Rabkin
Department of Psychiatry, Columbia University, New York, New York, USA
Muscle Nerve 39:297-303. 2009..The number needed to treat was 1.6 (ITT). No medically serious adverse events were reported. Modafinil may be a promising intervention for fatigue in ALS patients. Replication in a larger study is needed...
- The Timed Up and Go test: predicting falls in ALSJacqueline Montes
Department of Neurology, College of Physicians and Surgeons, The Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
Amyotroph Lateral Scler 8:292-5. 2007..The TUG test can guide management of patients with ALS; a time of 14 s can be used to prompt the recommendation for mobility aids to prevent falls...
- Motor unit number estimation (MUNE) in diseases of the motor neuron: utility and comparative analysis in a multimodal biomarker studyClifton L Gooch
Department of Neurology, University of South Florida College of Medicine, Tampa, FL 33612, USA
Suppl Clin Neurophysiol 60:153-62. 2009..These features make MUNE an important tool for both the study of the pathophysiology of the motor neuron diseases, as well as an important measure for incorporation into future clinical trials...
- Encephalitis-associated hospitalizations among American Indians and Alaska NativesJason M Mehal
Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, and Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia Public Health Program, Department of Family and Community Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico Northern Navajo Medical Center, Indian Health Service, Shiprock, New Mexico
Am J Trop Med Hyg 90:755-9. 2014..S. population, due particularly to lower rates in the elderly. Future community-based surveillance and mortality studies are needed to confirm these findings and examine reasons underlying the low rates of encephalitis in AI/AN people...
- Amyotrophic lateral sclerosis with ragged-red fibersMichio Hirano
Department of Neurology, Columbia University Medical Center, 3 317 Russ Berrie Medical Science Pavilion, 1150 St Nicholas Ave, New York, NY 10032, USA
Arch Neurol 65:403-6. 2008..Motor neuron diseases (amyotrophic lateral sclerosis [ALS] and spinal muscular atrophy [SMA]) have been rarely associated with mitochondrial respiratory chain defects...
- Woman with a 26-year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexesPaul H Gordon
Department of Neurology, Division of Movement Disorders, Columbia Presbyterian Medical Center, New York, New York 10032, USA
Mov Disord 19:950-61. 2004..A woman who had her first serious fall at age 48 years subsequently developed neurological symptoms. Her case is described, differential diagnoses are presented, pathology is discussed, and a final diagnosis is reached...
- A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosisPaul H Gordon
The Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Columbia University Medical Center, 710 West 168th Street, New York, New York 10032, USA
Muscle Nerve 39:858-60. 2009..Dose-ranging, futility, and selection trials are examples of Phase I and II trial designs that can be conducted without placebo groups...
- Olfactory ensheathing glia injections in Beijing: misleading patients with ALSSheena Chew
Department of Neurology, Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
Amyotroph Lateral Scler 8:314-6. 2007..Clinics that give experimental and potentially harmful treatments outside the construct of well-designed clinical trials put patients at risk and do a disservice to the ALS community...
- Amyotrophic lateral sclerosisPaul H Gordon
Eleanor and Lou Gehrig Muscular Dystrophy Association Amyotrophic Lateral Sclerosis Research Center, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Sci Aging Knowledge Environ 2003:dn2. 2003..Cognition, the extraocular muscles, and the urinary sphincters were spared. Respiratory muscle weakness was a late manifestation...
- Current clinical trials in amyotrophic lateral sclerosisJaydeep M Bhatt
Columbia University, Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Neurological Institute, New York, NY 10032, USA
Expert Opin Investig Drugs 16:1197-207. 2007..There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design...
- Lou Gehrig, rawhide, and 1938Melissa Lewis
Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Columbia University, New York, NY, USA
Neurology 68:615-8. 2007..A photograph of Gehrig from October 1939 showed hand atrophy. Photos from the spring of 1938 showed normal hand muscles and leg function, implying that visible signs first appeared after May 1938...
- Selecting promising ALS therapies in clinical trialsYing Kuen Cheung
Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY 10032, USA
Neurology 67:1748-51. 2006....
- Reaction time and movement time after embryonic cell implantation in Parkinson diseasePaul H Gordon
Department of Neurology and Clinical Motor Physiology Laboratory, Columbia Presbyterian Medical Center, New York, NY 10032, USA
Arch Neurol 61:858-61. 2004..Reaction time (RT) and movement time (MT) analysis, validated quantitative measures of premovement neural processing and motor execution, can be used as objective physiological markers of motor performance in PD...
- ALSFRS-RPaul H Gordon
Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, New York, NY 10032, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 5:90-3. 2004..Unlike the other standard outcome measures currently employed, the ALSFRS-R is also a measure of global function...
- Advances in clinical trials for amyotrophic lateral sclerosisPaul H Gordon
Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, 9th Floor, 710 West 168th Street, New York, NY 10032, USA
Curr Neurol Neurosci Rep 5:48-54. 2005..This article is devoted to the recent evolution of clinical trials in ALS and discusses specific trials conducted during the past 5 years...
- Minocycline-induced skin and dental pigmentationsTahseen Mozaffar
Department of Neurology, University of California, Irvine, 101 The City Drive South, Bldg 22 C, Route 13, Orange, CA 92868, USA
Neurology 67:2185. 2006
- Defining survival as an outcome measure in amyotrophic lateral sclerosisPaul H Gordon
Department of Neurology, Columbia University, New York, New York, USA
Arch Neurol 66:758-61. 2009..To examine how respiratory interventions affect survival as an outcome measure and to define survival rate for trials in amyotrophic lateral sclerosis...
- Oxidative stress biomarkers in sporadic ALSHiroshi Mitsumoto
Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University Medical Center, New York, NY 10032, USA
Amyotroph Lateral Scler 9:177-83. 2008..ELISA may be reliable and thus useful in epidemiology studies requiring large numbers of samples to determine the significance of increased oxidative stress markers in SALS. Further studies are required...